<p>Thurston Springer Miller Herd</p>
<p>&amp; Titak Inc. 在最近向美国证券交易委员会提交的 13F 文件中表示，在第二季度将其在礼来公司的股份增加了 10.8%。该公司在本季度额外购买了 1,862 股后，持有该公司 19,071 股股票。礼来公司约占 Thurston Springer Miller Herd</p>
<p>&amp; Titak Inc. 投资组合的 1.9%，使其成为该公司第六大持仓。截止最近报告期末，Thurston Springer Miller Herd</p>
<p>&amp; Titak Inc. 在礼来公司的持股价值为 14,868,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>先锋的 VUG ETF：您投资组合的终极增长 ETF</li>
</ul>
<p>其他机构投资者也增加或减少了在该公司的股份。WestEnd Advisors LLC 在第一季度将其在礼来公司的股份增加了 210.0%。WestEnd Advisors LLC 现在拥有 31 股该公司的股票，价值 26,000 美元，此前在此期间额外购买了 21 股。财富保护顾问公司在第一季度获得了礼来公司的新头寸，价值约 27,000 美元。公民国家银行信托部门在第一季度将其在礼来公司的股份增加了 180.0%。公民国家银行信托部门现在拥有 42 股该公司的股票，价值 35,000 美元，此前在此期间额外购买了 27 股。金融重力资产管理公司在第一季度获得了礼来公司的新头寸，价值约 40,000 美元。最后，Mascagni Wealth Management Inc. 在第四季度获得了礼来公司的新头寸，价值约 43,000 美元。82.53% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师观点</h2>
<p>几家券商最近对 LLY 发表了评论。德意志银行将礼来公司的目标价从 1,010.00 美元下调至 900.00 美元，并在 8 月 11 日的研究报告中对该公司给予了 “买入” 评级。大和美国在 8 月 17 日的研究报告中将礼来公司的评级从 “强力买入” 下调至 “持有”。Cantor Fitzgerald 在 8 月 13 日的研究报告中将礼来公司的目标价从 975.00 美元下调至 825.00 美元，并对该公司给予了 “增持” 评级。摩根士丹利在 7 月 10 日的研究报告中重申了 “增持” 评级，并对礼来公司的股票设定了 1,135.00 美元的目标价（高于 1,133.00 美元）。最后，瑞银集团在 8 月 8 日的研究报告中将礼来公司的目标价从 1,050.00 美元下调至 895.00 美元，并对该公司给予了 “买入” 评级。一位研究分析师对该股票给予了强力买入评级，十三位分析师给予了买入评级，八位分析师对该股票给予了持有评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 941.35 美元。</p>
<ul>
<li>随着市场轮动，这只医疗保健 ETF 引领潮流</li>
</ul>
<p><strong>查看我们关于礼来公司的最新报告</strong></p>
<h2>内部买卖</h2>
<p>在相关消息中，董事 J Erik Fyrwald 于 8 月 12 日购买了 1,565 股礼来公司的股票。该股票的平均购买价格为每股 642.33 美元，总交易额为 1,005,246.45 美元。交易完成后，该董事在公司持有 74,578 股股票，价值 47,903,686.74 美元。这笔交易代表了他们持股的 2.14% 增加。该收购在与证券交易委员会的法律文件中披露，您可以通过此链接访问。此外，首席执行官 David A. Ricks 于 8 月 12 日购买了 1,632 股礼来公司的股票。该股票的平均价格为每股 644.77 美元，总价值为 1,052,264.64 美元。交易完成后，首席执行官持有 546,601 股该公司的股票，价值 352,431,926.77 美元。这代表了他们持股的 0.30% 增加。该购买的披露信息可以在这里找到。内部人士在过去 90 天内购买了价值 2,894,841 美元的 4,514 股公司股票。公司内部人士持有该公司 0.13% 的股票。</p>
<h2>礼来公司价格表现</h2>
<ul>
<li>Ozempic 热潮：Hims 和礼来公司引领医疗保健投资</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）周五开盘价为 754.90 美元。该股票的 50 日简单移动平均线为 741.03 美元，200 日简单移动平均线为 776.40 美元。礼来公司的 1 年低点为 623.78 美元，1 年高点为 942.35 美元。该公司的市值为 714.48 亿美元，市盈率为 49.34，市盈增长比率为 1.05，贝塔值为 0.47。该公司的流动比率为 1.28，速动比率为 1.00，债务权益比率为 1.86。</p>
<p>礼来公司（NYSE:LLY - 获取免费报告）最后一次公布季度财报是在 8 月 7 日。该公司报告本季度每股收益为 6.31 美元，超出市场共识预期的 5.59 美元，超出幅度为 0.72 美元。礼来公司的股本回报率为 92.72%，净利润率为 25.91%。该公司本季度的收入为 155.6 亿美元，而分析师预期为 144.0 亿美元。在去年同期，该公司每股收益为 3.92 美元。与去年同期相比，礼来公司的收入增长了 37.6%。礼来公司已将其 2025 财年的指导目标设定为每股收益 21.750-23.000 美元。分析师预计礼来公司今年每股收益将达到 23.48 美元。</p>
<h2>礼来公司分红公告</h2>
<p>该公司最近宣布了季度股息，并于 9 月 10 日（星期三）支付。8 月 15 日（星期五）登记在册的股东获得了每股 1.50 美元的股息。除息日为 8 月 15 日（星期五）。这代表着每年 6.00 美元的股息和 0.8% 的股息收益率。礼来的派息比率为 39.22%。</p>
<h2>礼来公司简介</h2>
<p>（免费报告）</p>
<p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供用于糖尿病的 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素 lispro、胰岛素 lispro 原料、胰岛素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500；用于 2 型糖尿病的 Jardiance、Mounjaro 和 Trulicity；以及用于肥胖症的 Zepbound。</p>
<h2>另见</h2>
<ul>
<li>五只我们认为比礼来公司更好的股票</li>
<li>为什么投资高收益股息股票？</li>
<li>乘着奢侈零售浪潮，这三只高端品牌股票值得关注</li>
<li>选举股票：选举如何影响股市</li>
<li>华尔街悄然重注这些中国科技巨头</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>Meta 的 6000 亿美元美国投资：对股票是看跌还是看涨？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在礼来公司吗？</h2>
<p>在考虑投资礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>Thurston Springer Miller Herd & Titak Inc. 增加了对礼来的股份，增幅为 10.8%，额外购买了 1,862 股，使其总持股达到 19,071 股，价值约为 1487 万美元。机构投资者持有该股票的 82.53%。最近的分析师评级显示共识为 “适度买入”，目标价为 941.35 美元。内部交易包括董事 J Erik Fyrwald 和首席执行官 David A. Ricks 的购买，增加了他们的持股。礼来股票开盘价为 754.90 美元</p>

<p>Thurston Springer Miller Herd &amp; Titak Inc. increased its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 10.8% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 19,071 shares of the company's stock after buying an additional 1,862 shares during the quarter. Eli Lilly and Company comprises about 1.9% of Thurston Springer Miller Herd &amp; Titak Inc.'s portfolio, making the stock its 6th biggest position. Thurston Springer Miller Herd &amp; Titak Inc.'s holdings in Eli Lilly and Company were worth $14,868,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Thurston Springer Miller Herd</p>
<p>&amp; Titak Inc. 在最近向美国证券交易委员会提交的 13F 文件中表示，在第二季度将其在礼来公司的股份增加了 10.8%。该公司在本季度额外购买了 1,862 股后，持有该公司 19,071 股股票。礼来公司约占 Thurston Springer Miller Herd</p>
<p>&amp; Titak Inc. 投资组合的 1.9%，使其成为该公司第六大持仓。截止最近报告期末，Thurston Springer Miller Herd</p>
<p>&amp; Titak Inc. 在礼来公司的持股价值为 14,868,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio</li>
</ul>
<div class="lb-trans"><ul>
<li>先锋的 VUG ETF：您投资组合的终极增长 ETF</li>
</ul>
</div><p>Other institutional investors have also added to or reduced their stakes in the company. WestEnd Advisors LLC raised its stake in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after buying an additional 21 shares during the period. Wealth Preservation Advisors LLC acquired a new position in Eli Lilly and Company during the 1st quarter worth approximately $27,000. Citizens National Bank Trust Department raised its stake in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after buying an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new position in Eli Lilly and Company during the 1st quarter worth approximately $40,000. Finally, Mascagni Wealth Management Inc. acquired a new position in Eli Lilly and Company during the 4th quarter worth approximately $43,000. 82.53% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他机构投资者也增加或减少了在该公司的股份。WestEnd Advisors LLC 在第一季度将其在礼来公司的股份增加了 210.0%。WestEnd Advisors LLC 现在拥有 31 股该公司的股票，价值 26,000 美元，此前在此期间额外购买了 21 股。财富保护顾问公司在第一季度获得了礼来公司的新头寸，价值约 27,000 美元。公民国家银行信托部门在第一季度将其在礼来公司的股份增加了 180.0%。公民国家银行信托部门现在拥有 42 股该公司的股票，价值 35,000 美元，此前在此期间额外购买了 27 股。金融重力资产管理公司在第一季度获得了礼来公司的新头寸，价值约 40,000 美元。最后，Mascagni Wealth Management Inc. 在第四季度获得了礼来公司的新头寸，价值约 43,000 美元。82.53% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several brokerages have recently commented on LLY. Deutsche Bank Aktiengesellschaft lowered their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a &#34;buy&#34; rating for the company in a research note on Monday, August 11th. Daiwa America downgraded Eli Lilly and Company from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, August 17th. Cantor Fitzgerald lowered their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an &#34;overweight&#34; rating for the company in a research note on Wednesday, August 13th. Morgan Stanley reissued an &#34;overweight&#34; rating and issued a $1,135.00 price objective (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. Finally, UBS Group lowered their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a &#34;buy&#34; rating for the company in a research note on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $941.35.</p>
<div class="lb-trans"><p>几家券商最近对 LLY 发表了评论。德意志银行将礼来公司的目标价从 1,010.00 美元下调至 900.00 美元，并在 8 月 11 日的研究报告中对该公司给予了 “买入” 评级。大和美国在 8 月 17 日的研究报告中将礼来公司的评级从 “强力买入” 下调至 “持有”。Cantor Fitzgerald 在 8 月 13 日的研究报告中将礼来公司的目标价从 975.00 美元下调至 825.00 美元，并对该公司给予了 “增持” 评级。摩根士丹利在 7 月 10 日的研究报告中重申了 “增持” 评级，并对礼来公司的股票设定了 1,135.00 美元的目标价（高于 1,133.00 美元）。最后，瑞银集团在 8 月 8 日的研究报告中将礼来公司的目标价从 1,050.00 美元下调至 895.00 美元，并对该公司给予了 “买入” 评级。一位研究分析师对该股票给予了强力买入评级，十三位分析师给予了买入评级，八位分析师对该股票给予了持有评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，共识目标价为 941.35 美元。</p>
</div><ul>
<li>As the Market Rotates, This Healthcare ETF Is Leading the Way</li>
</ul>
<div class="lb-trans"><ul>
<li>随着市场轮动，这只医疗保健 ETF 引领潮流</li>
</ul>
</div><p><strong>Check Out Our Latest Report on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>查看我们关于礼来公司的最新报告</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In related news, Director J Erik Fyrwald purchased 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was bought at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is accessible through this link. Also, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares of the company's stock, valued at $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock valued at $2,894,841 in the last 90 days. Corporate insiders own 0.13% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 J Erik Fyrwald 于 8 月 12 日购买了 1,565 股礼来公司的股票。该股票的平均购买价格为每股 642.33 美元，总交易额为 1,005,246.45 美元。交易完成后，该董事在公司持有 74,578 股股票，价值 47,903,686.74 美元。这笔交易代表了他们持股的 2.14% 增加。该收购在与证券交易委员会的法律文件中披露，您可以通过此链接访问。此外，首席执行官 David A. Ricks 于 8 月 12 日购买了 1,632 股礼来公司的股票。该股票的平均价格为每股 644.77 美元，总价值为 1,052,264.64 美元。交易完成后，首席执行官持有 546,601 股该公司的股票，价值 352,431,926.77 美元。这代表了他们持股的 0.30% 增加。该购买的披露信息可以在这里找到。内部人士在过去 90 天内购买了价值 2,894,841 美元的 4,514 股公司股票。公司内部人士持有该公司 0.13% 的股票。</p>
</div><h2>Eli Lilly and Company Price Performance</h2>
<div class="lb-trans"><h2>礼来公司价格表现</h2>
</div><ul>
<li>Ozempic Boom: Hims &amp; Eli Lilly Lead Healthcare Bets</li>
</ul>
<div class="lb-trans"><ul>
<li>Ozempic 热潮：Hims 和礼来公司引领医疗保健投资</li>
</ul>
</div><p>Shares of NYSE LLY opened at $754.90 on Friday. The stock has a fifty day simple moving average of $741.03 and a two-hundred day simple moving average of $776.40. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $942.35. The firm has a market cap of $714.48 billion, a price-to-earnings ratio of 49.34, a price-to-earnings-growth ratio of 1.05 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）周五开盘价为 754.90 美元。该股票的 50 日简单移动平均线为 741.03 美元，200 日简单移动平均线为 776.40 美元。礼来公司的 1 年低点为 623.78 美元，1 年高点为 942.35 美元。该公司的市值为 714.48 亿美元，市盈率为 49.34，市盈增长比率为 1.05，贝塔值为 0.47。该公司的流动比率为 1.28，速动比率为 1.00，债务权益比率为 1.86。</p>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the company earned $3.92 earnings per share. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最后一次公布季度财报是在 8 月 7 日。该公司报告本季度每股收益为 6.31 美元，超出市场共识预期的 5.59 美元，超出幅度为 0.72 美元。礼来公司的股本回报率为 92.72%，净利润率为 25.91%。该公司本季度的收入为 155.6 亿美元，而分析师预期为 144.0 亿美元。在去年同期，该公司每股收益为 3.92 美元。与去年同期相比，礼来公司的收入增长了 37.6%。礼来公司已将其 2025 财年的指导目标设定为每股收益 21.750-23.000 美元。分析师预计礼来公司今年每股收益将达到 23.48 美元。</p>
</div><h2>Eli Lilly and Company Dividend Announcement</h2>
<div class="lb-trans"><h2>礼来公司分红公告</h2>
</div><p>The business also recently declared a quarterly dividend, which was paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th were given a $1.50 dividend. The ex-dividend date was Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is 39.22%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度股息，并于 9 月 10 日（星期三）支付。8 月 15 日（星期五）登记在册的股东获得了每股 1.50 美元的股息。除息日为 8 月 15 日（星期五）。这代表着每年 6.00 美元的股息和 0.8% 的股息收益率。礼来的派息比率为 39.22%。</p>
</div><h2>Eli Lilly and Company Company Profile</h2>
<div class="lb-trans"><h2>礼来公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供用于糖尿病的 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素 lispro、胰岛素 lispro 原料、胰岛素 lispro 混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500；用于 2 型糖尿病的 Jardiance、Mounjaro 和 Trulicity；以及用于肥胖症的 Zepbound。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>Why Invest in High-Yield Dividend Stocks?</li>
<li>Ride the Luxury Retail Wave with These 3 High-End Brand Stocks</li>
<li>Election Stocks: How Elections Affect the Stock Market</li>
<li>Wall Street Quietly Bets Big on These Chinese Tech Giants</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>Meta's $600B U.S. Investment: Bearish or Bullish for Shares?</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比礼来公司更好的股票</li>
<li>为什么投资高收益股息股票？</li>
<li>乘着奢侈零售浪潮，这三只高端品牌股票值得关注</li>
<li>选举股票：选举如何影响股市</li>
<li>华尔街悄然重注这些中国科技巨头</li>
<li>罗素 2000 指数，投资者如何利用它进行盈利交易</li>
<li>Meta 的 6000 亿美元美国投资：对股票是看跌还是看涨？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Thurston Springer Miller Herd & Titak Inc. 购入了礼来公司 1,862 股股票